NVIV - InVivo Therapeutics Holdings Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

InVivo Therapeutics Holdings Corp.

One Kendall Square
4th Floor Suite B14402 Building 1400 West
Cambridge, MA 02139
United States
617 863 5500

Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard M. ToselliPres, CEO, Chief Medical Officer & Director825.2kN/A1958
Mr. Richard C. ChristopherCFO & Treasurer537.82kN/A1970
Ms. Heather M. Hamel J.D.Chief Legal Officer & Gen. Counsel446.96kN/A1990
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCDCo-Founder & Member of Scientific Advisory BoardN/AN/A1949
Dr. Joseph Philip VacantiCo-FounderN/AN/A1949
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

InVivo Therapeutics Holdings Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.